Talphera (TLPH)
NASDAQ:TLPH
Want to see TLPH full AI Analyst Report?
Earnings Data
Report Date
Aug 19, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.06Last Year’s EPS
-0.1Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong clinical and operational momentum: enrollment has surpassed the 50% milestone, sites and KOLs reported favorable feedback on dosing simplicity and stability, and management expects a rapid top-line read in H2 2026 with a PMA plan for 2027. However, the company faces higher operating expenses and depends on two conditional financing tranches (~$16M) to fund the path to potential approval, with enrollment variability and financing contingency as primary risks. Overall, positive progress is balanced against execution and financing risk, but the highlights outweigh the lowlights.Company Guidance
Enrollment Progress & Milestones
Achieved the 50% enrollment milestone in early March 2026 and have since "well exceeded" 50%; company expects to complete enrollment in 2026 and to file a PMA for Niyad in 2027. 9 of 12 activated sites aligned with the new target profile and have enrolled over 90% of patients to date.
Site Quality, KOL and Investigator Support
Nephrologist-led sites and principal investigators are highly engaged; KOLs endorsed nafamostat as addressing an unmet need based on ~4 decades of use outside the U.S.; clinical staff reported strong enthusiasm and operational support for the NEPHRO study.
Operational & Clinical Performance (Dosing Stability)
Study design enables rapid data: primary endpoint at 24 hours and secondary at 72 hours. Bedside ACT monitoring showed ~70% of cases reach target ACT at the first starting dose, ~25% require one titration, and by the end of the first hour nearly all patients are in range — indicating dosing stability and simplicity of administration.
Cash Position and Financing Activity
Cash balance of $21.1M as of March 31, 2026; closed a $4.1M tranche in the quarter. Two remaining conditional financing tranches totaling approximately $16M are expected to close around the topline data/study completion, and management believes cash plus those tranches should provide sufficient capital through a potential Niyad PMA approval.
Fast Data Readout Expectation
Management expects to announce Last Patient Out (LPO) and then deliver top-line data within roughly one month after LPO due to the short (24/72 hour) endpoints; guidance remains for a top-line read in the second half of 2026.
TLPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TLPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $0.90 | $0.90 | -0.44% |
Mar 23, 2026 | $0.83 | $0.80 | -3.73% |
Nov 12, 2025 | $1.29 | $1.05 | -18.60% |
Aug 14, 2025 | $0.43 | $0.42 | -0.93% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Talphera (TLPH) report earnings?
Talphera (TLPH) is schdueled to report earning on Aug 19, 2026, After Close (Confirmed).
What is Talphera (TLPH) earnings time?
Talphera (TLPH) earnings time is at Aug 19, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TLPH EPS forecast?
TLPH EPS forecast for the fiscal quarter 2026 (Q2) is -0.06.